SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-24-008063
Filing Date
2024-05-14
Accepted
2024-05-14 07:45:14
Documents
14
Period of Report
2024-05-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K xlo-20240514x8k.htm   iXBRL 8-K 52430
2 EX-99.1 xlo-20240514xex99d1.htm EX-99.1 110155
  Complete submission text file 0001558370-24-008063.txt   300442

Data Files

Seq Description Document Type Size
3 EX-101.SCH xlo-20240514.xsd EX-101.SCH 3114
4 EX-101.LAB xlo-20240514_lab.xml EX-101.LAB 16578
5 EX-101.PRE xlo-20240514_pre.xml EX-101.PRE 10708
17 EXTRACTED XBRL INSTANCE DOCUMENT xlo-20240514x8k_htm.xml XML 5045
Mailing Address 828 WINTER STREET WALTHAM MA 02451
Business Address 828 WINTER STREET WALTHAM MA 02451 617-833-1027
Xilio Therapeutics, Inc. (Filer) CIK: 0001840233 (see all company filings)

IRS No.: 851623397 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40925 | Film No.: 24941487
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)